Hsbc Holdings PLC purchased a new position in shares of Allakos Inc. (NASDAQ:ALLK) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,310 shares of the company’s stock, valued at approximately $325,000.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its stake in Allakos by 11.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 985 shares of the company’s stock worth $138,000 after buying an additional 100 shares during the period. California State Teachers Retirement System grew its holdings in Allakos by 0.4% during the 3rd quarter. California State Teachers Retirement System now owns 36,865 shares of the company’s stock worth $3,003,000 after acquiring an additional 145 shares in the last quarter. Amalgamated Bank grew its holdings in Allakos by 7.9% during the 4th quarter. Amalgamated Bank now owns 4,085 shares of the company’s stock worth $572,000 after acquiring an additional 298 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Allakos by 6.3% during the 4th quarter. Victory Capital Management Inc. now owns 8,445 shares of the company’s stock worth $1,182,000 after acquiring an additional 502 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Allakos by 4.3% during the 3rd quarter. Wells Fargo & Company MN now owns 13,863 shares of the company’s stock worth $1,129,000 after acquiring an additional 573 shares in the last quarter. 65.35% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ ALLK opened at $104.46 on Wednesday. Allakos Inc. has a one year low of $55.51 and a one year high of $157.98. The company has a 50-day simple moving average of $116.36 and a 200-day simple moving average of $114.60. The firm has a market capitalization of $5.55 billion, a PE ratio of -38.12 and a beta of 1.02.
Allakos (NASDAQ:ALLK) last posted its quarterly earnings results on Sunday, February 28th. The company reported ($0.86) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.02. Equities research analysts expect that Allakos Inc. will post -3.08 earnings per share for the current year.
ALLK has been the subject of several recent analyst reports. SVB Leerink initiated coverage on shares of Allakos in a report on Monday, December 21st. They set an “outperform” rating for the company. Cantor Fitzgerald began coverage on shares of Allakos in a report on Wednesday, February 24th. They set an “overweight” rating and a $218.00 price objective for the company. Bank of America began coverage on shares of Allakos in a report on Friday, January 15th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Zacks Investment Research raised shares of Allakos from a “sell” rating to a “hold” rating in a report on Thursday, March 4th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Allakos presently has a consensus rating of “Buy” and an average target price of $167.67.
In other Allakos news, major shareholder Peter A. Hudson sold 2,200 shares of the business’s stock in a transaction dated Tuesday, March 9th. The shares were sold at an average price of $124.75, for a total transaction of $274,450.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Henrik S. Md Rasmussen sold 20,000 shares of the business’s stock in a transaction dated Monday, April 5th. The shares were sold at an average price of $113.06, for a total transaction of $2,261,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 206,460 shares of company stock valued at $24,563,967 over the last three months. 44.77% of the stock is currently owned by company insiders.
Allakos Inc operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc was founded in 2012 and is headquartered in Redwood City, California.
Read More: What is an Initial Coin Offering (ICO)?
Want to see what other hedge funds are holding ALLK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allakos Inc. (NASDAQ:ALLK).
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.